Kythera Biopharmaceuticals clinical trials

Acquired by AbbVie, May 8, 2020 · source ↗

The registry lists 23 studies whose lead sponsor is Kythera Biopharmaceuticals. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 17, 2020.

Studies

Recruiting first, then most recently updated. Showing 23 of 23. All AbbVie studies →

• Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedNCT02159729Phase 2

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental FatCompletedNCT02035267Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of AgeCompletedNCT02123134Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101CompletedNCT02163902Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Condition of Submental Fullness and Treatment Outcomes RegistryCompletedNCT02438813

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• To Evaluate the Safety, Tolerability and to Compare the Pharmacokinetic Profile of ATX-101CompletedNCT01462786Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Open-Label Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01426373Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Phase 2 Study for the Treatment of Superficial LipomasCompletedNCT00608842Phase 2

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Deoxycholic Acid Injection for the Treatment of Superficial LipomasCompletedNCT00422188Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Patient Experience Study of Deoxycholic Acid InjectionCompletedNCT02007434Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618618Phase 2

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental FatCompletedNCT00618722Phase 1/2

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatCompletedNCT01305577Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Deoxycholic Acid Injection Submental Fat (SMF) Magnetic Resonance Imaging (MRI) and Subject-reported Outcome Measures StudyCompletedNCT01032889Phase 2

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01542034Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental AreaCompletedNCT01546142Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Evaluation of Safety and Efficacy of Deoxycholic Acid Injection (ATX-101) in the Reduction of Submental FatCompletedNCT01294644Phase 3

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Dose-Escalation Safety and Pharmacokinetic Study of ATX-101CompletedNCT00618709Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Evaluation of the Effect of ATX-101 on QT/QTc IntervalsCompletedNCT01706679Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Open-Label Pharmacokinetic Study of Final Formulations of ATX-101CompletedNCT01632917Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• Lipid and Adipokine Profiles Following Subcutaneous Injection of ATX-101 Into Abdominal Fat TissueCompletedNCT01319916Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• A Study to Assess Injection Comfort of Two Formulations of ATX-101CompletedNCT01320761Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie

• ATX-101 AbdominoplastyCompletedNCT00835952Phase 1

  Sponsor listed in the registry: Kythera Biopharmaceuticals · First submitted before Kythera Biopharmaceuticals became part of AbbVie